
Porton Biopharma has signed a modification to its existing agreement with the US National Institute of Health’s National Institute of …

The US Food and Drug Administration (FDA) has approved Anthim (obiltoxaximab) to treat inhalational anthrax in combination with appropriate antibacterial …

Emergent BioSolutions is planning a major expansion of manufacturing capacity for its anthrax vaccine BioThrax to meet the biodefense objectives …


